As of November 6, 2026, Enliven Therapeutics, Inc. is a publicly traded company (Nasdaq: ELVN). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 9.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (15%), Polar Capital Holdings Plc (8.46%), Commodore Capital (7.7%) (Schedule 13D/A, June 24, 2026).
Is this your company?
About to sign with, pay or invest in Enliven Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Enliven Therapeutics, Inc. a real, registered company?
- Enliven Therapeutics, Inc. files with the SEC under CIK 1672619 (its SEC filings).
- Its shares are listed under the ticker ELVN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Burlingame, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Enliven Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Kristine Ball, Director (Form 8-K filed 2026-10-14). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Enliven Therapeutics, Inc.'s owners and officers?
Enliven Therapeutics, Inc.: incorporated in Delaware; business address in Burlingame, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-04-03)
- : Executive Officer, Director (Form D, 2024-04-03)
- : Executive Officer (Form D, 2024-04-03)
- : Executive Officer (Form D, 2024-04-03)
- : Executive Officer (Form D, 2024-04-03)
- : Director (Form D, 2024-04-03)
- : Director (Form D, 2024-04-03)
- : Director (Form D, 2024-04-03)
- : Director (Form D, 2024-04-03)
- : Director (Form D, 2024-04-03)
- : Director (Form D, 2024-04-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 7.1% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 15% |
| Schedule 13D/A, 2026-06-24 | Orbimed Advisors LLC | 9.5% |
| Schedule 13G/A, 2026-06-22 | Polar Capital Holdings PLC | 8.46% |
| Schedule 13D/A, 2026-06-17 | Orbimed Advisors LLC | 10.93% |
| Schedule 13G/A, 2026-05-15 | Vestal Point Capital, LP | 5.4% |
| Schedule 13G/A, 2026-05-15 | Commodore Capital LP | 7.7% |
| Schedule 13G/A, 2026-05-15 | Fairmount Funds Management LLC | 3.1% |
| Schedule 13G/A, 2026-05-15 | Polar Capital Holdings PLC | 8.46% |
| Schedule 13G/A, 2026-05-15 | Polar Capital Holdings PLC | 8.47% |
| Schedule 13G/A, 2026-05-15 | Venrock Healthcare Capital Partners Iii, L.P. | 2.8% |
| Schedule 13G, 2026-02-17 | Vestal Point Capital, LP | 6.5% |
Questions about who owns Enliven Therapeutics, Inc.
Who owns Enliven Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Enliven Therapeutics, Inc.: Fmr LLC (15%, Schedule 13G/A, filed 2026-08-06), Orbimed Advisors LLC (9.5%, Schedule 13D/A, filed 2026-06-24), Polar Capital Holdings PLC (8.46%, Schedule 13G/A, filed 2026-06-22), Commodore Capital LP (7.7%, Schedule 13G/A, filed 2026-05-15) and Blackrock, Inc. (7.1%, Schedule 13G/A, filed 2026-10-27); 1 more is listed above.
Who are the largest shareholders of Enliven Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Enliven Therapeutics, Inc. on this page are Fmr LLC (15%), Orbimed Advisors LLC (9.5%) and Polar Capital Holdings PLC (8.46%).
When did Fmr LLC buy into Enliven Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-08-06, reporting 15%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Enliven Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Enliven Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enliven Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-14 | Kristine Ball | Director | appointed | 2026-10-14 |
Which insiders own Enliven Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- OrbiMed Capital GP VII LLC, a 10% owner: 6,555,102 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-24).
- OrbiMed Genesis GP LLC, a 10% owner: 6,555,102 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-24).
- OrbiMed, a 10% owner: 6,555,102 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-24).
- , the chief executive and president: 890,392 shares (1.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-11-19).
- , the chief scientific officer: 758,938 shares (1.0% of shares outstanding), 18,750 held directly and 740,188 indirectly (Form 4, 2026-02-17).
Shares outstanding: 73,595,132 as of 2026-10-28, from the company's latest SEC cover page.
How much has Enliven Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-04-03 | $90M | $90M |
Keep reading
More on Enliven Therapeutics, Inc. and the records around it.
Enliven Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Oct 2026
Companies that share a holder
- Polar Capital Holdings Plc also filed stake reports on 3 other companies: Arcutis Biotherapeutics, Inc. (Aug 2026), Verastem, Inc. (Jul 2026), HAGERTY, INC. (Sep 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/enliven-therapeutics